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Abstract Evidence strongly indicates that extended RAS test-
ing should be undertaken in mCRC patients, prior to prescrib-
ing anti-EGFR therapies. With more laboratories implementing
testing, the requirement for External Quality Assurance
schemes increases, thus ensuring high standards of molecular
analysis. Data was analysed from 15 United KingdomNational
External Quality Assessment Service (UK NEQAS) for
Molecular Genetics Colorectal cancer external quality assur-
ance (EQA) schemes, delivered between 2009 and 2016.
Laboratories were provided annually with nine colorectal tu-
mour samples for genotyping. Information on methodology
and extent of testing coverage was requested, and scores given
for genotyping, interpretation and clerical accuracy. There has
been a sixfold increase in laboratory participation (18 in 2009 to
108 in 2016). For RAS genotyping, fewer laboratories now use
Roche cobas®, pyrosequencing and Sanger sequencing, with
more moving to next generation sequencing (NGS). NGS is the
most commonly employed technology for BRAF and PIK3CA
mutation screening. KRAS genotyping errors were seen in
≤10% laboratories, until the 2014–2015 scheme, when there
was an increase to 16.7%, corresponding to a large increase
in scheme participants. NRAS genotyping errors peaked at
25.6% in the first 2015–2016 scheme but subsequently dropped
to below 5%. Interpretation and clerical accuracy scores have
been consistently good throughout. Within this EQA scheme,
we have observed that the quality of molecular analysis for
colorectal cancer has continued to improve, despite changes
in the required targets, the volume of testing and the technolo-
gies employed. It is reassuring to know that laboratories clearly
recognise the importance of participating in EQA schemes.
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Introduction
Precision medicine is now very much a key element in clinical
oncology. The identification of several biomarkers along with
the advent of targeted therapies has changed the landscape of
cancer treatment. One example can be found in relation to co-
lorectal cancer (CRC), where over recent years, it has become a
requirement that patients with mCRC undergo RAS mutation
screening, prior to being offered anti-EGFR therapies, as it has
been shown that patients with wildtype (WT) RAS may gain
benefit from such treatments [3, 5, 11, 14, 19], whereas those
with mutated RAS may in fact experience detrimental effects.
Laboratories providing such molecular biomarker testing
in routine practice must ensure that this work is carried out
to the highest possible standards, and this should bemonitored
and assessed as part of a national or international external
quality assurance (EQA) scheme, where possible. Indeed, this
is now a requirement for laboratories in order to meet
ISO15189 accreditation https://www.ukas.com/services/
accreditation-services/medical-laboratory-accreditation-iso-
15189/.
The results obtained in the laboratory have direct implica-
tions upon patient treatment and as such must be accurate and
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reproducible to provide the best patient management and
avoid over-treating or denying therapy to patients.
Participation in an EQA scheme does improve the quality
of molecular pathology testing, demonstrated by the decrease
of the percentage of participants with genotyping errors fol-
lowing continual participation [7–9, 22]. Results from two
CRC national EQA schemes have been recently published.
The Italian RAS EQA scheme reported 38% of 88 participat-
ing laboratories failed the first round of their testing program,
but 72% of these participants passed the second round of
testing, taking the overall pass rate to almost 90% [13]. In
Germany, 11/74 (14.9%) participating laboratories failed the
KRAS quality assurance scheme set up by the German Society
for Pathology in conjunction with the Federation of the
German Pathologist [1].
In the Netherlands, 17 Dutch laboratories each sent 10
CRC samples to a reference laboratory for re-testing of
KRAS,NRAS and BRAFmutation status. All mutations report-
ed by the participating laboratories were detected by the ref-
erence laboratory, plus an additional 10mutations. These were
not originally detected due to the testing strategy employed
not covering those particular mutations [6].
Furthermore, several Europe-wide schemes have been run-
ning successful EQA schemes over the past few years, includ-
ing the European Society of Pathology (ESP KRAS EQA) [4].
In the most recently published scheme, 27% of participants
incorrectly genotyped at least one of the 10 samples received
as part of the scheme, and 20% of participants reported a
technical error for at least one sample [17].
The United KingdomNational External Quality Assessment
Service (UKNEQAS) forMolecular Genetics scheme for CRC
was established in 2009. It provides assessment of the accuracy
and appropriateness of laboratories’ molecular testing of colo-
rectal cancer samples, the interpretation of the result and the
clerical accuracy of the report and promotes good practice
through educational comments. We report here on the data col-
lected from all 15 of the UK NEQAS colorectal EQA schemes,
from the first scheme in 2009, with 18 participants, to the most
recent 2015–2016 scheme with 108 participating laboratories
from both the UK and worldwide. The data analysed includes
participant numbers, methodologies employed, genotyping
panels and genotyping error rates.
Materials and methods
The UKNEQAS for Molecular Genetics EQA scheme for the
molecular analysis of colorectal cancer samples was first in-
troduced in 2009. The first two assessments were provided
annually and following the identification of many critical
genotyping errors, subsequent schemes (2011–2012, 2012–
2013 and 2013–2014) each comprised of three runs per year.
As participant numbers increased and to enable the inclusion
of an appeals process, this was reduced to two runs per year,
from 2014 to 2015 onwards. This currently conforms to ISO/
IEC 17043:2010 (http://www.iso.org).
For each EQA year, formalin-fixed, paraffin-embedded
(FFPE) colorectal tumour blocks were retrieved from histopa-
thology departments to provide nine EQA cases. The genotyp-
ing status of each block was confirmed and validated by at
least two independent laboratories, using multiple testing
methodologies on FFPE sections prepared throughout the
blocks, prior to distribution. Multiple sections from the top,
middle and lower portions of the tumour blocks were subject-
ed to mutation status testing, to rule out tumour heterogeneity.
Participating laboratories could receive either (a) three
slide-mounted 5 μm sections only, (b) two rolled 5 μm tissue
sections plus a slide-mounted section or (c) three rolled 5 μm
sections. Further data on this aspect from the 2014–2015 and
2015–2016 schemes is available elsewhere. (15).
From the initial EQA run until the end of the first run in
2013–2014, only KRAS genotyping was assessed. Run 2 of
the 2013–2014 scheme introduced genotyping of NRAS as a
pilot scheme, enabling participants to determine the standard
of theirNRAS testing, reflecting the change in clinical practice.
The phasing in of a pilot gene ensured that no laboratory
would be classed as a poor performer if a critical genotyping
error was reported for NRAS during implementation of diag-
nostic testing. This pilot status remained in place during run 3
of 2013–2014. Laboratories are permitted to submit their
genotyping results for BRAF and PIK3CA if routinely
screened but were not asked to make a clinical interpretation
based upon these results. Furthermore, laboratories were told
not to report any additional results, outside of those requested
as part of the EQA scheme.
A mock clinical case scenario was supplied with each sam-
ple, and laboratories were asked to make a clinical interpreta-
tion of the RAS genotyping results, in relation to the clinical
scenario, and provide information as to the methodology
employed for mutation detection, the sensitivity of their tests,
and also on which genes were assessed.
An evaluation of each laboratory submission was
made by two independent assessors against peer-
ratified criteria, then each result reviewed by a panel
of assessors. All submissions were anonymised so im-
partiality was maintained by the assessors. A maximum
of two marks was awarded for genotyping accuracy,
which included the correct use of HGVS nomenclature.
A maximum of two marks was available for the appro-
priate interpretation of the result, and a maximum of
two marks was also available for clerical accuracy of
the report.
Any critical genotyping errors were followed up by UK
NEQAS and help, support and education offered to identify
and correct the cause of the erroneous result(s). Following
each scheme, each laboratory was sent a tailored report,
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detailing how their individual laboratory had scored for each
sample tested. There was also a defined period of time
where any laboratories wishing to appeal their results
could do so. UK NEQAS then distributed a final scheme
report, detailing the correct genotyping results and stat-
ing the average scores for genotyping, interpretation and
clerical accuracy across all laboratories, as well as
discussing any issues arising for the EQA run. Any rel-
evant publications were highlighted in the scheme re-
port, to inform laboratories of current suggested testing
guidelines, and implications for clinical interpretation.
Results
Scheme participation
The number of participating laboratories rose steadily from
the first EQA scheme, in 2009 (Fig. 1). The most marked
increase was between the third run of 2013–2014 and the first
run of 2014–2015, with an additional 20 laboratories partici-
pating. Overall, there has been a sixfold increase in the num-
ber of laboratories taking part in the scheme, since its incep-
tion. In the 2009 scheme, 47% were UK-based and 53% were
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Fig. 1 The number of
participating laboratories
registering for the EQA scheme
each year
Table 1 The three most
commonly used screening
methodologies for mutation
screening of KRAS, NRAS, BRAF
and PIK3CA in the last three EQA
years
Scheme year/gene Most common
methodology
Second most common
methodology
Third most common
methodology
2013–2014
KRAS Roche cobas® Pyrosequencing Sanger sequencing
NRAS Pyrosequencing Sanger sequencing Mass spectrometry
BRAF Roche cobas® Pyrosequencing Sanger Sequencing
PIK3CA Roche cobas® Mass spectrometry
(Sequenom)
Pyrosequencing
2014–2015
KRAS Sanger sequencing Roche cobas® Pyrosequencing
NRAS Sanger sequencing Pyrosequencing NGS
BRAF Sanger sequencing Pyrosequencing NGS
PIK3CA NGS Sanger sequencing a
2015–2016
KRAS Sanger sequencing NGS Pyrosequencing
NRAS Pyrosequencing Sanger sequencing NGS
BRAF NGS Pyrosequencing Sanger sequencing
PIK3CA NGS Sanger sequencing Mass spectrometry (Sequenom)
a Pyrosequencing, Roche cobas® and mass spectrometry (Sequenom) all equally place third
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international, whereas in the most recent run, as numbers in-
creased, these figures were and 29 and 71%, respectively.
Mutation detection methodology
The method, or in some cases, multiple methodologies used
by participating laboratories was reviewed in detail for the
three most recent EQA years (2013–2014, 2014–2015 and
2015–2016), thus providing data on seven consecutive runs.
The total number of uses for each particular methodology was
determined for each EQA year, and then this total used to
determine the ranking order.
Table 1 shows the three most common methodologies
employed for mutation screening of KRAS, NRAS, BRAF
and PIK3CA. One of the most striking observations is the
significant decrease in the usage of the Roche cobas® plat-
form, possibly reflecting its limited coverage of mutation
hotspots and the lack of ability to differentiate between
mutations detected. Pyrosequencing and Sanger Sequencing
still remain popular platforms, but the use of next generation
sequencing (NGS) has significantly increased, becoming the
most commonly used methodology for BRAF and PIK3CA
screening and the 2nd and 3rd most common for KRAS and
NRAS, respectively.
Mutation detection testing combinations
There has been a marked decrease in the percentage of labo-
ratories testing only KRAS, and an increase in the percentage
testing both KRAS and NRAS. Overall, there has been a trend
towards an increase in testing the combination of KRAS and
NRAS and BRAF, and also an increase in the testing of KRAS,
NRAS, BRAF and PIK3CA. No laboratories in the 2015–2016
scheme were reporting the combination of KRAS plus BRAF,
whereas in 2013–2014, this figure was 33.9 and 26.7% of
laboratories respectively for runs 1 and 2 (see Table 2).
Table 2 Percentage of laboratories performing each of the genotyping testing combinations. As several laboratories employmore than one technology,
the columns may exceed 100%
Genotyping testing combination 2013–2014 2013–2014 2013–2014 2014–2015 2014–2015 2015–2016 2015–2016
Run 1
n = 58
Run 2
n = 61
Run 3
n = 64
Run 1
n = 84
Run 2
n = 84
Run 1
n = 99
Run 2
n = 108
KRAS only 49.2 38.3 23.8 14.3 10.7 11.2 8.2
KRAS + NRAS 0 1.7 12.7 27.4 33.3 40.8 34.7
KRAS + NRAS + BRAF 0 11.7 31.7 31.0 31.0 23.5 36.7
KRAS + NRAS + BRAF + PIK3CA 0 16.7 22.2 20.2 21.4 22.4 30.6
KRAS + NRAS + PIK3CA 0 1.7 1.6 1.2 1.2 1.0 0
KRAS + BRAF + PIK3CA 16.9 3.3 1.6 2.4 1.2 1.0 1.0
KRAS + BRAF 33.9 26.7 6.3 3.6 1.2 0 0
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Fig. 2 The percentage of
laboratories in each scheme run,
reporting a genotyping error in
one of both of the RAS genes
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Genotyping errors
For each EQAyear, the total number of laboratories reporting
errors in RAS (KRAS and NRAS) genotyping was determined
(Fig. 2). This figure remained below 10% from the initial
scheme in 2009, up to, and including Run 2 of the 2013–
2014 scheme. The number of laboratories reporting RAS
genotyping errors peaked at 33.3% in the initial run of the
2015–2016 scheme but dropped back down to 10.2% in the
subsequent run.
Figure 3 shows the data when the KRAS and NRAS
genotyping errors were analysed separately. For KRAS, the
percentage of laboratories reporting genotyping errors
remained below 10% from the first scheme in 2009 up to
and including Run 3 of the 2013–2014 scheme. The rise to
16.7% in 2014–2015, correspondedwith a significant increase
in the number of laboratories participating in the scheme (64
in 2013–2014 Run 3, and 84 in 2014–2015 Runs 1 and 2), and
furthermore, the majority of laboratories reporting incorrect
KRAS genotypes were new participants to the scheme. The
percentage reporting errors fell during the 2015–2016
schemes to 6.5% in the most recent run. When NRAS was
introduced as a pilot scheme, in Run 2 of the 2013–2014
scheme, all of the 19 laboratories who reported a NRAS
genotyping result reported it correctly. Over the next three
runs, the percentage reporting incorrect NRAS genotype re-
sults increased but remained relatively stable between 10.4
and 11.6% but peaked at 25.6% in the first run of the 2015–
2016 scheme, finally falling to 4% in the final run analysed.
Unlike with the KRAS genotyping errors, the majority of
NRAS genotyping errors in the first 2015–2016 scheme could
not be attributed to new participating laboratories.
Table 3 shows the type of genotyping errors being reported
by laboratories, across all EQA runs, for KRAS. By far, the
most common error was the reporting of a false negative re-
sult, in samples where a validated mutation had been identi-
fied. The 2014–2015 scheme and Run 1 of the 2015–2016
scheme showed an increase in the number of errors being
reported. In each case, there were laboratories with multiple
genotyping errors.
Table 4 shows the type of genotyping errors made by lab-
oratories for NRAS. The large increase in Run 1 of 2015–2016
in the number of false negatives was partly a result of several
laboratories using a TIBMOLBIOLLightmix kit, which failed
to detect the NRAS mutation. No other correlations were seen
between the methodologies used and genotyping errors
reported.
Interpretation and clerical errors
Not all laboratories submitted a specific clinical interpretation,
in addition to the genotyping results. For those laboratories
that did, each was expected to additionally report the reference
sequence for each gene tested; the assay sensitivity (i.e., the
percentage of mutant DNA that could be detected in a back-
ground of wild type DNA); a statement indicating that an
assessment of the tumour had been made, and the percentage
of tumour cells in the assessed area or a statement indicating
that no assessment was made; the methodology employed and
the scope of each assay (i.e., which mutations could be detect-
ed and in which codons or exons).
The most common errors made, which each resulted
in the loss of 0.5 marks, were a lack of a gene refer-
ence sequence being stated and a statement of assay
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Fig. 3 Percentage of laboratories
with KRAS and NRAS genotyping
errors. (NRAS was only
introduced into the EQA scheme
in the second run of 2013–2014)
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sensitivity, which was of particular importance in cases
which were wild type for all assays performed. Marks
were seldom deducted for clerical accuracy errors, al-
though occasionally a typographical error in the patient
name or date of birth was present, and in which case,
appropriate deductions were made. A total of 2.0 marks
were available for both interpretation and clerical accu-
racy. Table 5 shows the mean scores in both categories
for each scheme year.
Discussion
We have now entered the era of personalised medicine with
biomarker mutation status becoming an essential requirement,
prior to the prescribing of particular targeted therapies. It has
been long established that mutated KRAS is a negative predic-
tive biomarker of response to Panitumumab [3] and
Cetuximab [5, 20]. More recently, guidelines have been up-
dated to reflect the findings of several studies, which showed
that activating mutations outside of just KRAS exon 2 were
also predictive of response to anti-EGFR therapies [10, 21].
The European Medicines Agency (EMA) now state that
patients must be WT for exons 2, 3 and 4 of both KRAS and
NRAS, prior to therapy. In the UK, the recommendation that
KRAS codons 12–13, 59, 61, 117 and 146 and NRAS 12–13,
59 and 61 has been proposed by the Association of Clinical
Pathologists Molecular Pathology and Diagnostic Group [23].
As the requirement for extended testing panels increases to
influence patient management, there becomes the need to en-
sure that such testing is accurate across all targets tested. Since
2009, the UKNEQAS for Molecular Genetics Colorectal can-
cer EQA scheme has been providing assessments and has
tracked the changes employed by laboratories.
The increased number of genes to be tested testing brings
with it the inevitable need for larger quantities of DNA for
molecular testing unless methods are changed to allow parallel
testing. We have seen a shift in the most commonly used
testing methodologies, reflecting this requirement, with more
laboratories employing more sensitive NGS techniques which
also enable multiple genes and/or gene regions to be tested at
the same time. In the most recent run, 25 laboratories reported
using NGS for both KRAS and NRAS testing, making it the
most common method of screening. Similarly, 23 and 18
Table 3 Types of genotyping errors reported in KRAS testing
EQA year
and Run
Number of laboratories
reporting genotyping
errors (%)
Total number of
errors reported
False positive
results reported
False negative
results reported
Incorrect mutation
reported
aExtra mutation
reported (not present)
2009 1 (5.5) 1 0 1 0 0
2010 2 (4.9) 5 1 2 2 0
2011–2012
Run 1
5 (9.8) 8 0 7 1 0
2011–2012
Run 2
2 (4.2) 8 1 1 6 0
2011–2012
Run 3
5 (9.6) 5 0 3 2 0
2012–2013
Run 1
3 (5.2) 4 2 2 0 0
2012–2013
Run 2
1 (1.5) 1 1 0 0 0
2012–2013
Run 3
2 (3.0) 2 0 2 0 0
2013–2014
Run 1
2 (3.4) 3 1 2 0 0
2013–2014
Run 2
2 (3.3) 2 0 2 0 0
2013–2014
Run 3
4 (6.3) 4 0 2 2 0
2014–2015
Run 1
9 (10.7) 15 8 6 1 0
2014–2015
Run 2
14 (16.7) 16 2 12 1 1
2015–2016
Run 1
13 (13.1) 25 8 11 6 0
2015–2016
Run 2
7 (6.5) 11 8 1 0 2
a Extra mutations differed to a false positive result, as these mutations were detected in addition to the mutation actually present in the sample, rather than
being detected in a wildtype sample, which was classed as a false positive result
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laboratories stated that NGS was used to genotype BRAF and
PIK3CA, respectively. Although Sanger Sequencing and
Pyrosequencing still remain the next most popular choices,
as testing panels expand to incorporate additional genes, one
may assume that the number of laboratories able to still em-
ploy these methods will decrease, and this is indicated in the
increasing number of laboratories participating in the UK
NEQAS NGS technical somatic EQA scheme.
Since the first run of the 2013–2014 scheme, there has been
a significant decrease in the number of laboratories reporting
only the KRAS mutation status, with a drop from 49.1 to just
8.2%. It is encouraging to see that laboratories are realising the
need to test additional genes. In run 2 of the 2013–14 scheme,
when NRAS genotyping was introduced as a pilot scheme,
only 1.7% of laboratories reported anNRAS genotyping result.
This increased to 40.8% in the first run of the 2015–2016
scheme but fell to 34.7% in the second run. This slight
decrease was a result of the increase in the number of new
participating laboratories with only KRAS testing employed
and NRAS testing not yet implemented.
There has been an increase in the percentage testing KRAS,
NRAS and BRAF, up to 36% in the most recent scheme run.
Mutated BRAF is a poor prognostic marker [15, 16, 18]; how-
ever, the predictive significance still remains controversial,
and thus BRAF genotyping currently is not a requirement un-
der UK recommendations, ASCO guidelines or EMA guide-
lines [2, 23]. The prognostic significance and relationship with
microsatellite instability (MSI) status is most likely what
drives clinical laboratories to currently perform BRAF
genotyping.
Almost one-third (30.6%) of laboratories carried out
genotyping of KRAS, NRAS, BRAF and PIK3CA in the
most recent scheme. This was an increase of just over
8% on the previous run and is likely the result of the
Table 5 The mean interpretation
and clinical accuracy scores for
participating laboratories across
all scheme years. A maximum of
2.00 marks was available for each
category
EQA year; run Mean interpretation
score (max 2.00)
Mean clinical accuracy
score (max 2.00)
2009 Not marked Not marked
2010 1.82 1.99
2011–2012; Run 1 1.44 1.93
2011–2012; Run 2 1.68 1.93
2011–2012; Run 3 1.84 1.98
2012–2013; Run 1 1.90 1.98
2012–2013; Run 2 1.92 1.98
2012–2013; Run 3 1.84 1.98
2013–2014; Run 1 1.93 1.98
2013–2014; Run 2 1.98 1.99
2013–2014; Run 3 1.97 2.00
2014–2015; Run 1 1.90 1.99
2014–2015; Run 2 1.93 1.98
2015–2016; Run 1 1.93 1.99
2015–2016; Run 2 1.89 1.99
Table 4 Types of genotyping errors seen in NRAS testing
EQA year and Run Number of
laboratories reporting
genotyping errors (%)
Total number of
errors reported
False positive
results reported
False negative
results reported
Incorrect mutation
reported
Extra mutation
reported (not present)
2013–2014
Run 2
0 0 0 0 0 0
2013–2014
Run 3
5 (11.6) 5 1 4 0 0
2014–2015
Run 1
7 (10.4) 8 5 1 2 0
2014–2015
Run 2
8 (10.9) 8 4 3 1 0
2015–2016
Run 1
22 (25.6) 29 2 23 4 0
2015–2016
Run 2
4 (4.0) 4 1 1 0 2
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increased use of NGS testing panels, which incorporate
these genes in addition to KRAS, NRAS and many
others. This is the reason for UK NEQAS to include multiple
genes into the assessment to provide participants with a mea-
sure of the accuracy of this testing along with the assessment
of the clinically actionable genes.
Genotyping errors, whether false positive, and thus poten-
tially depriving patients of therapy, or false negative, and po-
tentially exposing patients to treatments which will provide no
benefit, and may in fact be detrimental [11, 12], were reported
at varying levels across all EQA runs. Run 2 of 2013–2014
saw only 1.5% of the 65 participating laboratories reporting an
incorrect genotype, but this figure peaked at 33.3% in the first
run of 2015–2016. Thirteen of the 99 laboratories reported a
total of 23 KRAS genotyping errors, and 33 of the 86 labora-
tories carrying out NRAS mutation screening, reported a total
of 29 errors. Laboratories reporting errors in NRAS during the
second and third run of 2013–2014 were not considered ‘poor
performers’ as for these two runs only, the NRAS scheme was
given pilot status. One reason for this large increase in the
number incorrect NRAS genotyping errors was the use by
several laboratories of a commercial kit, not designed to iden-
tify the particular NRAS mutation, carried by one of the tu-
mours; c.181C > A p.(Gln61Lys). This resulted in a signifi-
cant increase in the number of false negative results.
It is worth noting that each sample is assessed in the refer-
ence laboratories for tumour cell content. None of the samples
used in the EQA scheme had a tumour cell content of less than
20%, thus removing this as a reason for false negative results.
Several laboratories state the mutant allele frequencies within
their reports, and these are above the sensitivity levels of all
technologies employed by participating laboratories.
In general, those laboratories choosing to submit a clinical
interpretation do so with a high degree of accuracy. There was
only one scheme run where the mean score dropped below
1.50/2.00. During this particular run, only two (of the three)
cases were marked, which clearly impacted upon the mean
interpretation score.
When comparing the overall performance of laboratories
taking part in the UK NEQAS EQA scheme, with those of
other comparable schemes, it would appear that participants in
this scheme do substantially better. This may be due in part, to
the obvious shift we have seen, to more sensitive testing tech-
nologies, such as NGS. Participants have responded positively
to feedback given by the scheme and have taken corrective
action to previous errors. Furthermore, our data show that
there tends to be a small number of laboratories, making mul-
tiple errors, which has a lessening impact on the overall
scheme results, given the large numbers of participating labo-
ratories in the UK NEQAS scheme.
This EQA scheme has been running for 8 years, expanding
almost every year, as increasingly laboratories realise the ne-
cessity and indeed benefits of scheme participation.
Continued scheme participation will ensure continued valida-
tion of methodologies which may require modification over
time, to cope with the ever-increasing demands placed on
laboratories for additional biomarker testing. EQA schemes
such as this will remain critical to ensuring accurate genotyp-
ing and thus guiding personalised medicine.
Compliance with ethical standards
Conflict of interest SDR, honoraria from UK NEQAS for Molecular
Genetics; RB, Astra Zeneca, Merck Serono and Pfizer; advisory role
payment from Astra Zeneca andMerck Serono; additional expenses from
Astra Zeneca, Merck Serono and Pfizer; ZCD, honoraria from Astra
Zeneca and Pfizer; advisory role payments from Astra Zeneca, Amgen
and Pfizer.
Ethical responsibilities of authors All authors made substantial con-
tributions to the manuscript concept, critical revision for intellectual con-
tent, final approval of the submitted version and are accountable for all
aspects of the work.
Research support SDR was funded by Medical Research Council
(MRC)-SCORT. ZCD and JF were funded by UK NEQAS for
Molecular Genetics.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. A. Jung GB, M.Dietel, H. Gabbert, H.Kreipe, W. Schlake, A.
Tannapfel, M. von Knebel Doberitz and T. Kirchner (2009) The
German quality assurance system for the molecular-pathological
detection of KRAS-mutations in colorecal cancer ASCO Annual
meeting, pp 4018
2. Allegra CJ, Rumble RB, Schilsky RL (2016) Extended RAS gene
mutation testing in metastatic colorectal carcinoma to predict re-
sponse to anti-epidermal growth factor receptor monoclonal anti-
body therapy: American Society of Clinical Oncology provisional
clinical opinion update 2015 summary. J Oncol Pract 12:180–181.
doi:10.1200/JOP.2015.007898
3. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman
DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang
DD (2008) Wild-type KRAS is required for panitumumab efficacy
in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–
1634. doi:10.1200/JCO.2007.14.7116
4. Bellon E, Ligtenberg MJ, Tejpar S, Cox K, de Hertogh G, de
Stricker K, Edsjo A, Gorgoulis V, Hofler G, Jung A, Kotsinas A,
Laurent-Puig P, Lopez-Rios F, Hansen TP, Rouleau E,
Vandenberghe P, van Krieken JJ, Dequeker E (2011) External qual-
ity assessment for KRAS testing is needed: setup of a European
program and report of the first joined regional quality assessment
rounds. Oncologist 16:467–478. doi:10.1634/theoncologist.2010-
0429
5. Bokemeyer C, Bondarenko I, Hartmann JT, de Braud F, Schuch G,
Zubel A, Celik I, Schlichting M, Koralewski P (2011) Efficacy
according to biomarker status of cetuximab plus FOLFOX-4 as
Virchows Arch
first-line treatment formetastatic colorectal cancer: the OPUS study.
Ann Oncol 22:1535–1546. doi:10.1093/annonc/mdq632
6. Boleij A, Tops BB, Rombout PD, Dequeker EM, Ligtenberg MJ,
van Krieken JH, Dutch RASEQAI (2015) RAS testing in metastatic
colorectal cancer: excellent reproducibility amongst 17 Dutch pa-
thology centers. Oncotarget 6:15681–15689. doi: 10.18632/
oncotarget.3804
7. Deans ZC, Bilbe N, O'Sullivan B, Lazarou LP, de Castro DG, Parry
S, Dodson A, Taniere P, Clark C, Butler R (2013) Improvement in
the quality of molecular analysis of EGFR in non-small-cell lung
cancer detected by three rounds of external quality assessment. J
Clin Pathol 66:319–325. doi:10.1136/jclinpath-2012-201227
8. Deans ZC, Tull J, Beighton G, Abbs S, Robinson DO, Butler R
(2011) Molecular genetics external quality assessment pilot scheme
for KRAS analysis in metastatic colorectal cancer. Genet Test Mol
Biomarkers 15:777–783. doi:10.1089/gtmb.2010.0239
9. Deans ZC, Wallace A, O'Sullivan B, Purvis A, Camus S, Fairley
JA, Gonzalez D (2014) External quality assessment of BRAF mo-
lecular analysis in melanoma. J Clin Pathol 67:120–124. doi:10.
1136/jclinpath-2013-201848
10. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel
M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F,
Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon
JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R,
Patterson SD (2013) Panitumumab-FOLFOX4 treatment and
RAS mutations in colorectal cancer. N Engl J med 369:1023–
1034. doi:10.1056/NEJMoa1305275
11. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, BarugelM,
Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F,
Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon
JL, Rother M, Oliner KS, Wolf M, Gansert J (2010) Randomized,
phase III trial of panitumumab with infusional fluorouracil,
leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone
as first-line treatment in patients with previously untreated metasta-
tic colorectal cancer: the PRIME study. J ClinOncol 28:4697–4705.
doi:10.1200/JCO.2009.27.4860
12. Heinemann V, Douillard JY, Ducreux M, Peeters M (2013)
Targeted therapy in metastatic colorectal cancer—an example of
personalised medicine in action. Cancer Treat rev 39:592–601.
doi:10.1016/j.ctrv.2012.12.011
13. Normanno N, Pinto C, Castiglione F, Fenizia F, Barberis M,
Marchetti A, Fontanini G, De Rosa G, Taddei GL (2015) The
Italian external quality assessment for RAS testing in colorectal
carcinoma identifies methods-related inter-laboratory differences.
J Transl med 13:287. doi:10.1186/s12967-015-0655-1
14. Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko
Y, Andre T, Chan E, Lordick F, Punt CJ, Strickland AH, Wilson G,
Ciuleanu TE, Roman L, Van Cutsem E, Tzekova V, Collins S,
Oliner KS, Rong A, Gansert J (2010) Randomized phase III study
of panitumumab with fluorouracil, leucovorin, and irinotecan
(FOLFIRI) compared with FOLFIRI alone as second-line treatment
in patients with metastatic colorectal cancer. J Clin Oncol 28:4706–
4713. doi:10.1200/JCO.2009.27.6055
15. Richman SD, SeymourMT, Chambers P, Elliott F, Daly CL,Meade
AM, Taylor G, Barrett JH, Quirke P (2009) KRAS and BRAF
mutations in advanced colorectal cancer are associated with poor
prognosis but do not preclude benefit from oxaliplatin or irinotecan:
results from the MRC FOCUS trial. J Clin Oncol 27:5931–5937.
doi:10.1200/JCO.2009.22.4295
16. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR,
Murtaugh MA, Wolff RK, Slattery ML (2005) Poor survival asso-
ciated with the BRAF V600E mutation in microsatellite-stable co-
lon cancers. Cancer res 65:6063–6069. doi:10.1158/0008-5472.
CAN-05-0404
17. Tembuyser L, Ligtenberg MJ, Normanno N, Delen S, van Krieken
JH, Dequeker EM (2014) Higher quality of molecular testing, an
unfulfilled priority: results from external quality assessment for
KRAS mutation testing in colorectal cancer. The Journal of
Molecular Diagnostics : JMD 16:371–377. doi:10.1016/j.jmoldx.
2014.01.003
18. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A,
Maru DM, Sieber O, Desai J (2011) Impact of BRAF mutation and
microsatellite instability on the pattern of metastatic spread and
prognosis in metastatic colorectal cancer. Cancer 117:4623–4632.
doi:10.1002/cncr.26086
19. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien CR,
Makhson A, D'Haens G, Pinter T, Lim R, Bodoky G, Roh JK,
Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J,
Rougier P (2009) Cetuximab and chemotherapy as initial treatment
for metastatic colorectal cancer. N Engl J med 360:1408–1417. doi:
10.1056/NEJMoa0805019
20. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP,
Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S,
Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011)
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-
line treatment for metastatic colorectal cancer: updated analysis of
overall survival according to tumor KRAS and BRAF mutation
status. J Clin Oncol 29:2011–2019. doi:10.1200/JCO.2010.33.
5091
21. Van Cutsem E, Lenz HJ, Kohne CH, Heinemann V, Tejpar S,
Melezinek I, Beier F, Stroh C, Rougier P, van Krieken JH,
Ciardiello F (2015) Fluorouracil, leucovorin, and irinotecan plus
cetuximab treatment and RAS mutations in colorectal cancer. J
Clin Oncol 33:692–700. doi:10.1200/JCO.2014.59.4812
22. Wong NA, Deans ZC, Ramsden SC (2012) The UK NEQAS for
molecular genetics scheme for gastrointestinal stromal tumour:
findings and recommendations following four rounds of circula-
tion. J Clin Pathol 65:786–790. doi:10.1136/jclinpath-2012-200851
23. Wong NA, Gonzalez D, Salto-Tellez M, Butler R, Diaz-Cano SJ,
Ilyas M, Newman W, Shaw E, Taniere P, Walsh SV, Association of
Clinical Pathologists Molecular P, Diagnostics G (2014) RAS test-
ing of colorectal carcinoma—a guidance document from the
Association of Clinical Pathologists Molecular Pathology and
Diagnostics Group. J Clin Pathol 67:751–757. doi:10.1136/
jclinpath-2014-202467
Virchows Arch
